scispace - formally typeset
M

Michael D. Raleigh

Researcher at University of Minnesota

Publications -  23
Citations -  580

Michael D. Raleigh is an academic researcher from University of Minnesota. The author has contributed to research in topics: Oxycodone & Opioid. The author has an hindex of 11, co-authored 19 publications receiving 483 citations.

Papers
More filters
Journal ArticleDOI

Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats.

TL;DR: Data support the possibility of co-administering two or more opioid vaccines concurrently to target multiple abusable opioids without compromising the immunogenicity or efficacy of the individual components.
Journal ArticleDOI

Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse

TL;DR: In vitro receptor binding assays showed that antibody-bound oxycodone does not activate mu opioid receptors, which supports further study of OXY-dKLH as a potential treatment for oxy codone abuse and suggests that vaccination might also reduce the severity of oxycod one overdose.
Journal ArticleDOI

Selective Effects of a Morphine Conjugate Vaccine on Heroin and Metabolite Distribution and Heroin-Induced Behaviors in Rats

TL;DR: Data support a critical role for 6-MAM in mediating the early effects of i.v. heroin and suggest that reducing 6- MAM concentration in brain is essential to the efficacy of morphine conjugate vaccines.
Journal ArticleDOI

A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats

TL;DR: Preclinical selectivity and efficacy of a fentanyl vaccine are demonstrated and it is suggested that vaccines may offer a therapeutic option in reducing fentanyl-induced side effects.
Journal ArticleDOI

Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats

TL;DR: In this paper, 6-monoacetylmorphine (6-MAM) was the predominant opioid in plasma and brain as early as 1 minute after i.v. administration of heroin and for up to 14 minutes.